Acquisitions and Divestitures - Additional Information (Details) - USD ($)				1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2020	May 03, 2019	Mar. 30, 2019	Apr. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 10, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill					$ 527,475,000		$ 527,475,000		$ 419,504,000		$ 426,226,000
Net revenue					464,662,000	$ 404,642,000	963,195,000	$ 850,762,000
Operating loss					10,751,000	(18,913,000)	68,542,000	(113,273,000)
Amortization expense from intangible assets					43,976,000	34,796,000	86,552,000	65,759,000
Gain (loss) on sale of international businesses					123,000	(1,888,000)	123,000	6,930,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Creo Pharma Holding Limited
Business Acquisition [Line Items]
Ownership percentage sold (percent)			100.00%
Cash consideration, subsidiary				$ 32,000,000
Carrying value, net assets			$ 22,000,000
Carrying value, intangible assets sold			7,000,000
Carrying value, goodwill			$ 5,000,000
Gain (loss) on sale of international businesses					100,000			9,000,000
Loss on disposition of business, recognition of foreign currency translation adjustments								3,000,000
Payment for final settlement of the divestiture					500,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amneal Deutschland GmbH subsidiary ("ADG")
Business Acquisition [Line Items]
Ownership percentage sold (percent)		100.00%
Cash consideration, subsidiary		$ 3,000,000
Carrying value, net assets		7,000,000
Carrying value, goodwill		$ 500,000
Gain (loss) on sale of international businesses						$ (2,000,000)		$ (2,000,000)
Disposal Group, Disposed of by Sale, Not Discontinued Operations | AI Sirona | Creo Pharma Holding Limited
Business Acquisition [Line Items]
Supply agreement period (up to)			2 years
AvKARE
Business Acquisition [Line Items]
Goodwill					73,000,000		73,000,000
Net revenue					63,847,000		121,817,000
Generics
Business Acquisition [Line Items]
Goodwill					36,000,000		36,000,000
Term Loan
Business Acquisition [Line Items]
Debt, face amount	$ 180,000,000
AvKARE and R&S Acquisitions
Business Acquisition [Line Items]
Voting interest acquired (percent)	65.10%									65.10%
Total consideration, net of cash acquired	$ 294,833,000
Consideration paid in cash on hand	254,000,000
Liabilities incurred, fair value	11,000,000
Working capital costs	2,000,000
Acquisition, transaction costs					0		1,000,000
Goodwill					108,790,000		108,790,000
Net revenue					67,000,000		132,000,000
Operating loss					3,000,000		1,000,000
Amortization expense from intangible assets					8,000,000		14,000,000
AvKARE and R&S Acquisitions | Short Term Promissory Note
Business Acquisition [Line Items]
Liabilities incurred	1,000,000
AvKARE and R&S Acquisitions | Cash on Hand
Business Acquisition [Line Items]
Consideration paid in cash on hand	76,000,000
AvKARE and R&S Acquisitions | Long Term Promissory Notes
Business Acquisition [Line Items]
Liabilities incurred	44,000,000
Liabilities incurred, fair value	35,033,000
AvKARE and R&S Acquisitions | Debt
Business Acquisition [Line Items]
Consideration paid in cash on hand	$ 178,000,000
AvKARE | AvKARE
Business Acquisition [Line Items]
Goodwill					$ 73,000,000		$ 73,000,000